[go: up one dir, main page]

AR107426A1 - DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7 - Google Patents

DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7

Info

Publication number
AR107426A1
AR107426A1 ARP170100186A ARP170100186A AR107426A1 AR 107426 A1 AR107426 A1 AR 107426A1 AR P170100186 A ARP170100186 A AR P170100186A AR P170100186 A ARP170100186 A AR P170100186A AR 107426 A1 AR107426 A1 AR 107426A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heterocyclic ring
halogen
cycloalkyl
Prior art date
Application number
ARP170100186A
Other languages
English (en)
Inventor
Katy White
Martin Teall
Stephen Mack
Gemma Liwicki
Anne Goldby
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR107426A1 publication Critical patent/AR107426A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/30—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la terapia de trastornos auditivos y del SNC. Reivindicación 1: Un compuesto de fórmula (1) donde R¹ representa hidroxilo, -CH₂OH, ciano, -SO₂R¹ᵃ, -(CH₂)ₘ-(O)ₙ-R⁵ o (CH₂)ₚNR⁶R⁷; m es 0 ó 1; n es 0 ó 1; p es 0 ó 1; R¹ᵃ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆; cada uno de R² y R³ representa independientemente hidrógeno, halógeno, fluorometilo, difluorometilo, trifluorometilo, metoxi, fluorometoxi, difluorometoxi o trifluorometoxi; cualquier R⁴ᵃ representa (X)ₜ-(CH₂)ᵛ-R¹⁶ o -CH₂O-R¹⁷ y R⁴ᵇ representa hidrógeno, metilo o flúor, o R⁴ᵃ y R⁴ᵇ, junto con el átomo de carbono al cual se acoplan, forman un anillo heterocíclico o carbocíclico saturado de 3 a 6 miembros, donde el anillo heterocíclico comprende al menos un heteroátomo anular que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo carbocíclico o heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, oxo, alquilo C₁₋₃, alcoxi C₁₋₃, amino, metilamino, dimetilamino y haloalquilo C₁₋₃; R⁵ representa un grupo cicloalquilo C₃₋₆, un anillo heterocíclico de 4 a 6 miembros que contiene un heteroátomo anular individual que es un átomo de nitrógeno donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente seleccionado de halógeno, alquilo C₁₋₃ y haloalquilo C₁₋₃ o un grupo alquilo C₁₋₆ que no está sustituido o está sustituido con al menos un sustituyente seleccionado de cicloalquilo C₃₋₆, NR²²R²³ y un anillo heterocíclico saturado de 4 a 6 miembros que comprende al menos un heteroátomo anular que se selecciona de átomos de nitrógeno y oxígeno, donde dicho anillo heterocíclico no está sustituido o está sustituido con halógeno; cada uno de R⁶ y R⁷ representa independientemente hidrógeno, -(CH₂)q-R⁸, -SO₂R⁹, alquilo C₁₋₆, alquilcarbonilo C₁₋₆, cicloalquilcarbonilo C₃₋₆ o alcoxicarbonilo C₁₋₆, donde cada uno de los restos alquilo, cicloalquilo o alcoxi en los últimos cuatro sustituyentes no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, alcoxi C₁₋₄ y -NR¹⁰R¹¹, o R⁶ y R⁷, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado o no saturado de 4 a 7 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de nitrógeno, oxígeno y azufre, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, ciano, alquilo C₁₋₆, cicloalquilo C₃₋₆, cicloalquilmetilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquiloxi C₃₋₆, cicloalquilmetiloxi C₃₋₆ y -NR¹²R¹³; q es 0, 1 ó 2; R⁸ representa un anillo carbocíclico o heterocíclico saturado o no saturado de 3 a 6 miembros donde el anillo heterocíclico comprende de 1 a 4 heteroátomos anulares que se seleccionan independientemente de nitrógeno, oxígeno y azufre, donde el anillo carbocíclico o heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno, ciano, alquilo C₁₋₆, cicloalquilo C₃₋₆, cicloalquilmetilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquiloxi C₃₋₆, cicloalquilmetiloxi C₃₋₆ y -NR¹⁴R¹⁵; R⁹ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, cada uno de los cuales no está sustituido o está sustituido con al menos un átomo de halógeno; cada uno de R¹⁰ y R¹¹ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹⁰ y R¹¹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R¹² y R¹³ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹² y R¹³, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R¹⁴ y R¹⁵ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R¹⁴ y R¹⁵, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; t es 0 ó 1; v es 0, 1 ó 2; R¹⁶ representa -R¹⁷, -NR¹⁸R¹⁹ o un anillo heterocíclico saturado o no saturado de 4 a 6 miembros que comprende de 1 a 4 heteroátomos anulares que se seleccionan independientemente de nitrógeno, oxígeno y azufre, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente seleccionado de oxo, halógeno, ciano, fluorometoxi, difluorometoxi, trifluorometoxi, alquilo C₁₋₆, alcoxi C₁₋₆ y haloalquilo C₁₋₆; X es O, NH, -NHC(O)-, -NHC(O)O-, -C(O)NH-, -NHSO₂- o -SO₂NH-, siempre que cuando X sea O, NH, -C(O)NH- o -SO₂NH- y R¹⁶ represente -NR¹⁸R¹⁹, v sea 2; R¹⁷ representa alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, cada uno de los cuales no está sustituido o está sustituido con al menos un sustituyente que se selecciona de hidroxilo, halógeno y -NR²⁰R²¹; cada uno de R¹⁸ y R¹⁹ representa independientemente hidrógeno, alquilo C₁₋₆, alquilcarbonilo C₁₋₆, cicloalquilcarbonilo C₃₋₆, alquilsulfonilo C₁₋₆ o cicloalquilsulfonilo C₃₋₆, donde cada uno de los restos alquilo o cicloalquilo en los últimos cinco sustituyentes no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alcoxi C₁₋₄, o R¹⁸ y R¹⁹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; cada uno de R²⁰ y R²¹ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R²⁰ y R²¹, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; y cada uno de R²² y R²³ representa independientemente hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ o cicloalquilmetilo C₃₋₆, o R²² y R²³, junto con el átomo de nitrógeno al cual se acoplan, forman un anillo heterocíclico saturado de 4 a 6 miembros que comprende opcionalmente un heteroátomo anular adicional que se selecciona de átomos de nitrógeno y oxígeno, donde el anillo heterocíclico no está sustituido o está sustituido con al menos un sustituyente que se selecciona de halógeno y alquilo C₁₋₃; siempre que el compuesto de fórmula (1) no sea N-[(1S,2S)-1-amino-2,3-dihidro-1H-inden-2-il]-1-(4-fluorofenil)ciclopropano-1-carboxamida; o una sal farmacéuticamente aceptable de este.
ARP170100186A 2016-01-25 2017-01-25 DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7 AR107426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1601301.3A GB201601301D0 (en) 2016-01-25 2016-01-25 Novel compounds

Publications (1)

Publication Number Publication Date
AR107426A1 true AR107426A1 (es) 2018-04-25

Family

ID=55534857

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100186A AR107426A1 (es) 2016-01-25 2017-01-25 DERIVADOS DE N-INDEN-AMIDA COMO MODULADORES DEL mGluR7

Country Status (25)

Country Link
US (1) US20190031599A1 (es)
EP (1) EP3408256A1 (es)
JP (1) JP2019508390A (es)
KR (1) KR20180108600A (es)
CN (1) CN108602760A (es)
AR (1) AR107426A1 (es)
AU (1) AU2017210803A1 (es)
BR (1) BR112018015247A2 (es)
CA (1) CA3012443A1 (es)
CL (1) CL2018002010A1 (es)
CO (1) CO2018007610A2 (es)
EA (1) EA201891680A1 (es)
EC (1) ECSP18056196A (es)
GB (1) GB201601301D0 (es)
HK (1) HK1257091A1 (es)
MA (1) MA43922A (es)
MX (1) MX2018009078A (es)
PE (1) PE20181333A1 (es)
PH (1) PH12018501563A1 (es)
SG (1) SG11201804899YA (es)
TN (1) TN2018000175A1 (es)
TW (1) TW201733977A (es)
UY (1) UY37084A (es)
WO (1) WO2017131221A1 (es)
ZA (1) ZA201803520B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
JP7453365B2 (ja) * 2020-05-29 2024-03-19 富士フイルム富山化学株式会社 高純度のｎ－（５－メトキシ―２－フェノキシフェニル）メタンスルホンアミド及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK626889A (da) * 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
DE4220353A1 (de) * 1992-06-22 1993-12-23 Boehringer Ingelheim Kg Verwendung carbocyclisch und heterocyclisch annelierter Dihydropyridine als Mittel mit antiproliferativer Wirkung
CA2138788A1 (en) * 1992-06-22 1994-01-06 Dietrich Arndts Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions
AU8875798A (en) * 1997-08-29 1999-03-22 Proteus Molecular Design Ltd Meta-benzamidine derivatives as serin protease inhibitors
EP1192132B1 (en) * 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
MXPA02000242A (es) * 1999-06-30 2004-09-10 Prescient Neuropharma Inc Analogos de 2-aminoindano.
EP1193248A1 (en) * 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
DE10108307A1 (de) * 2001-02-21 2002-08-29 Gruenenthal Gmbh Substituierte Propan-1,3-diamin-Derivate
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
PT1751131E (pt) * 2004-03-10 2009-02-13 Janssen Pharmaceutica Nv Aril-piperidinas ou aril-piperazinas substituídas com heterociclos de 5 membros inibidoras de mtp
AU2005270377A1 (en) * 2004-08-09 2006-02-16 Glaxo Group Limited Compounds which potentiate glutamate receptor and uses thereof in medicine
CN101248046A (zh) * 2005-07-11 2008-08-20 德福根有限公司 作为激酶抑制剂的酰胺衍生物
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists

Also Published As

Publication number Publication date
KR20180108600A (ko) 2018-10-04
EP3408256A1 (en) 2018-12-05
ECSP18056196A (es) 2018-08-31
WO2017131221A1 (en) 2017-08-03
CA3012443A1 (en) 2017-08-03
UY37084A (es) 2017-08-31
GB201601301D0 (en) 2016-03-09
US20190031599A1 (en) 2019-01-31
CO2018007610A2 (es) 2018-07-31
MA43922A (fr) 2018-12-05
JP2019508390A (ja) 2019-03-28
HK1257091A1 (zh) 2019-10-11
PE20181333A1 (es) 2018-08-20
ZA201803520B (en) 2019-03-27
CN108602760A (zh) 2018-09-28
CL2018002010A1 (es) 2019-03-15
MX2018009078A (es) 2018-11-09
EA201891680A1 (ru) 2019-01-31
SG11201804899YA (en) 2018-07-30
TN2018000175A1 (en) 2019-10-04
AU2017210803A1 (en) 2018-07-19
TW201733977A (zh) 2017-10-01
PH12018501563A1 (en) 2019-05-15
BR112018015247A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR126406A2 (es) Compuestos de tetrazolinona y su uso
AR110922A1 (es) Compuestos inhibidores del vih
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR104513A1 (es) Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR101208A1 (es) Espirocicloheptanos como inhibidores de rock
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR112804A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR094550A1 (es) Inhibidores de btk
AR098492A1 (es) Derivados de purina
AR113886A1 (es) Derivados de indol macrocíclicos
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR092347A1 (es) Derivados de azaindol
AR113888A1 (es) Derivados de indol macrocíclicos sustituidos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR111271A1 (es) Inhibidores dobles de magl y faah
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR098436A1 (es) Compuestos tricíclicos de piperidina
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure